CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
about
Routine viral load monitoring versus standard care for reducing morbidity and mortality in adolescent and adult patients living with HIV on antiretroviral therapy (ART)Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDSCurrent Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral TherapyImmuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexusImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Casp8p41: The Protean Mediator of Death in CD4 T-cells that Replicate HIVChallenges in the treatment of HIV and HCV coinfection.Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients.CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility.Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan AfricaImpact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa.Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational DatabasePrevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.Antiretroviral therapy in the clinicTime to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia.Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisMaraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women.Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa.Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDSHepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa.AIDS-related cancer and severity of immunosuppression in persons with AIDS.Predictors of immunological failure of antiretroviral therapy among HIV infected patients in Ethiopia: a matched case-control studyCost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur.Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique.Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapySmall intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral loadImmunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cellsAssessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention.
P2860
Q24203980-EB4F3FD9-67C4-46D3-A3AB-F50240EADEBFQ24685909-3169C5AC-DB42-4DEC-BB78-6315A2684EC9Q26750980-807E1899-6611-40A5-ACB2-94FDAF17C4E6Q26991958-4072F399-F622-41D5-AFA9-6C4F60E07D19Q27687272-51F6B639-F01C-4D68-AF1D-7F23762E8F12Q28069817-D97D0908-CCDD-465D-BB29-0AA85B2FF2D8Q30389282-1BF66A00-E4DF-4F8F-BE60-0CCDB3924BFCQ31131058-750D7AF2-1102-4A8E-8CD3-0E39E02AD8F4Q33237178-1B1ACD97-6050-495C-8B47-133B1DC23288Q33322949-9B7307E5-351C-409B-A8C0-C93754CC97B9Q33535469-B5172B8B-740F-40E4-B03C-4F7C1EAA0A5DQ33580153-27CF0AF0-BA31-4F51-99B8-D7939F32BFE7Q33631238-6E71F666-01BE-4511-9B24-DC14F84CDF5BQ33779622-D7E0A11B-42AC-429E-B487-D739270270E7Q33781469-359C756A-A69D-4F95-A458-0DEDD879F868Q33877347-67EC9416-37B9-409C-B159-94998B2C76B6Q33909241-8B36ECEE-9CBD-470C-BC52-1207280196EEQ33933071-7553F295-4970-427E-9DD5-E5E8751DB1FEQ33950833-FF924840-5488-498D-8897-08401F030F4AQ33976854-2B64A2C1-29D1-4E53-B125-4DDDD22AA6CFQ34082897-6B688D29-173F-46B9-9AD2-2E8F3DD61210Q34126302-C62F2949-0F0E-4989-BBE7-FE3BC9D016A7Q34163380-555566E0-747E-4C40-8C38-073C26731A4AQ34332293-7C2CFB82-A9D3-424B-A3E3-6A7B2BCBDB18Q34356110-FCDE56D4-6658-429B-A08C-714DEAA0E713Q34427088-8A2B8DD5-3066-4EC9-B10F-FEAF4453F2ABQ34456352-9CE9C8FB-2970-43A8-AA1B-55D282051B56Q34569382-D14581B9-670E-49E9-B3F6-FA2395706EB7Q34583843-9DB56B41-6F07-4DA9-BF5D-41F41B3ACF53Q34636933-09E811F7-FE2E-435E-9858-ACA479D71A86Q34764695-16034308-227C-4859-B6C9-BD64353F6DD0Q34768650-03F27F04-36C0-4D19-879C-2A254F79946EQ34802246-9C4F229B-A443-44AF-B276-549441E466A8Q34937231-18F41F27-BABD-4B76-BA65-62798144C66BQ34981015-182685A4-26E8-42FF-BBE3-1344F08A33B2Q35077691-1549DBE6-5331-4FA9-BC4F-AC240D484F92Q35088585-1956614F-B342-4D87-83AD-6CA2918C2A14Q35336419-CA534016-D688-4A2D-8356-1D73DF56D360Q35557198-C5DB07DA-5E35-42A7-BE82-70D417594FB5Q35591286-3167FDB2-E604-40C6-A34A-499D4CF62550
P2860
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@ast
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@en
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@nl
type
label
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@ast
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@en
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@nl
prefLabel
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@ast
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@en
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@nl
P2093
P50
P921
P1476
CD4 T-lymphocyte recovery in i ...... s: the Swiss HIV Cohort Study.
@en
P2093
Amalio Telenti
Bruno Ledergerber
Gilbert R Kaufmann
Guiseppe Pantaleo
Luc Perrin
Martin Rickenbach
Milos Opravil
Pietro Vernazza
Swiss HIV Cohort Study Group
P304
P356
10.1001/ARCHINTE.163.18.2187
P407
P577
2003-10-01T00:00:00Z